Format

Send to

Choose Destination
Nat Rev Drug Discov. 2017 Sep;16(9):603-616. doi: 10.1038/nrd.2017.46. Epub 2017 May 12.

The antifungal pipeline: a reality check.

Author information

1
Duke University Medical Center, 200 Trent Drive, Durham, North Carolina 27710, USA.

Abstract

Invasive fungal infections continue to appear in record numbers as the immunocompromised population of the world increases, owing partially to the increased number of individuals who are infected with HIV and partially to the successful treatment of serious underlying diseases. The effectiveness of current antifungal therapies - polyenes, flucytosine, azoles and echinocandins (as monotherapies or in combinations for prophylaxis, or as empiric, pre-emptive or specific therapies) - in the management of these infections has plateaued. Although these drugs are clinically useful, they have several limitations, such as off-target toxicity, and drug-resistant fungi are now emerging. New antifungals are therefore needed. In this Review, I discuss the robust and dynamic antifungal pipeline, including results from preclinical academic efforts through to pharmaceutical industry products, and describe the targets, strategies, compounds and potential outcomes.

PMID:
28496146
PMCID:
PMC5760994
DOI:
10.1038/nrd.2017.46
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center